Neoadjuvant HER2+


The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Latest News

Christian Jackisch, MD, PhD
Subcutaneous Pertuzumab/Trastuzumab Maintains Comparable Efficacy/Safety vs IV Formulations in HER2+ Breast Cancer

June 7th 2024

Long-term outcomes with subcutaneous pertuzumab/trastuzumab plus chemo were comparable to the IV combo in HER2+ early breast cancer.

Erika Hamilton, MD, of Sarah Cannon Research Institute
Second-Line T-DXd Data Remain Strong in HER2+ Metastatic Breast Cancer

June 5th 2024

Atezolizumab plus neoadjuvant   pertuzumab, trastuzumab,   in HER2-positive early breast cancer.
Atezolizumab Elicits Numerical Improvement in 3-Year EFS, DFS in HER2+ Early Breast Cancer

May 30th 2024

HER2+ Breast Cancer | Image Credit: © Sebastian Kaulitzki -
Real-World Study Sheds Light on Treatment Sequences and Second-Line Outcomes in HER2+ Breast Cancer

May 19th 2024

T-DXd in HER2+ Metastatic Breast Cancer | Image Credit: © Axel Kock -
T-DXd Maintains Survival Advantage Over Physician’s Choice of Therapy in HER2+ Metastatic Breast Cancer

May 16th 2024

More News